• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

AlzeCure Pharma

4.28 SEK

+8.08 %

Less than 1K followers

ALZCUR

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+8.08 %
+245.36 %
+155.19 %
+144.34 %
+107.95 %
+58.25 %
-10.60 %
-30.76 %
-48.39 %

AlzeCure Pharma is a pharmaceutical company that researches and develops small molecule drug candidates for the treatment of diseases of the central nervous system, with a particular focus on Alzheimer's and chronic pain. The company is developing several parallel projects where the technology and research are based on its own drug platform. AlzeCure Pharma is headquartered in Huddinge, Sweden.

Read more
Market cap
590.2M SEK
Turnover
5.51M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
3rd party
ShowingAll content types

Financial calendar
26/8
2026

Interim report Q2'26

11/11
2026

Interim report Q3'26

23/2
2027

Annual report '26

Press release6/10/2026, 10:58 AM

Redeye: AlzeCure Pharma: From lab to Lilly – A historic USD1bn validation

AlzeCure Pharma
Regulatory press release6/9/2026, 5:10 AM

AlzeCure Pharma ingår samarbets- och utlicensieringsavtal med Lilly för Alzheimerprojekt

AlzeCure Pharma
Regulatory press release6/9/2026, 5:10 AM

AlzeCure Pharma enters into a collaboration and out-licensing agreement with Lilly for Alzheimer’s project

AlzeCure Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release6/5/2026, 6:00 AM

AlzeCure Pharma genomför tidigare aviserad företrädesemission om ca 30,1 MSEK och offentliggör informationsdokument

AlzeCure Pharma
Regulatory press release6/5/2026, 6:00 AM

AlzeCure Pharma carries out previously announced rights issue of approximately SEK 30.1 million and publishes information document

AlzeCure Pharma
Regulatory press release5/26/2026, 6:00 AM

KALLELSE TILL ÅRSSTÄMMA I ALZECURE PHARMA AB

AlzeCure Pharma
Regulatory press release5/26/2026, 6:00 AM

NOTICE TO ANNUAL GENERAL MEETING IN AlzeCure Pharma AB

AlzeCure Pharma
Press release5/19/2026, 8:00 AM

AlzeCure Pharma livesänder seminarium om smärtprojektet TrkA-NAM ACD137 med fokus på artros och nervsmärta

AlzeCure Pharma
Press release5/19/2026, 8:00 AM

AlzeCure Pharma to host live seminar on the pain project TrkA-NAM ACD137 with a focus on osteoarthritis and neuropathic pain

AlzeCure Pharma
Press release5/13/2026, 10:00 AM

AlzeCure Pharma to present at Redeye Investor Forum Online on May 21

AlzeCure Pharma
Press release5/13/2026, 10:00 AM

AlzeCure Pharma presenterar på Redeye Investor Forum Online den 21 maj

AlzeCure Pharma
Press release5/13/2026, 8:00 AM

AlzeCure Pharma to present at ABG Investor Days on May 21

AlzeCure Pharma
Press release5/13/2026, 8:00 AM

AlzeCure Pharma presenterar på ABG Investor Days den 21 maj

AlzeCure Pharma
Third party research5/12/2026, 6:03 AM

AlzeCure Pharma: Klinisk studie avslutad - Analysguiden

Alzecures fas 1b-studie med ACD856 på fyrtio friska frivilliga deltagare är slutförd enligt plan. Högre dos och längre duration har testats och verkar bekräfta den positiva säkerhetsprofilen i tidigare fas 1-studier. Nästa steg i detta innovativa projekt...

AlzeCure Pharma
Press release5/12/2026, 6:00 AM

Analysguiden: ANALYS AlzeCure Pharma: Klinisk studie avslutad

AlzeCure Pharma
Press release5/8/2026, 8:16 AM

Redeye: AlzeCure Pharma (Q1 Review): Advancing toward Phase IIa with NeuroRestore ACD856

AlzeCure Pharma
Press release5/6/2026, 8:00 AM

Ny vetenskaplig artikel publicerad om TrkA-NAM ACD137 mot osteoartros smärta

AlzeCure Pharma
Press release5/6/2026, 8:00 AM

New scientific article published on TrkA-NAM ACD137 against osteoarthritic pain

AlzeCure Pharma
Regulatory press release5/5/2026, 6:00 AM

AlzeCure offentliggör delårsrapport för januari – mars 2026

AlzeCure Pharma
Regulatory press release5/5/2026, 6:00 AM

AlzeCure publishes its interim report for January – March 2026

AlzeCure Pharma